Three Drugs for Atopic Dermatitis (Adbry, Cibinqo, and Rinvoq)
Three Drugs for Atopic Dermatitis (Adbry, Cibinqo, and Rinvoq)
April 3, 2023 (Issue: 1673)
The subcutaneously injected interleukin-13 (IL-13)
antagonist tralokinumab-ldrm (Adbry – Leo) and
the oral Janus kinase (JAK) inhibitors abrocitinib
(Cibinqo – Pfizer) and upadacitinib (Rinvoq – Abbvie)
have been approved by the FDA for...more
- Dupilumab (Dupixent) for moderate to severe atopic dermatitis. Med Lett Drugs Ther 2017; 59:64.
- Dupilumab (Dupixent) for asthma. Med Lett Drugs Ther 2019; 61:6.
- Upadacitinib (Rinvoq) – a new JAK inhibitor for rheumatoid arthritis. Med Lett Drugs Ther 2019; 61:183.
- Ruxolitinib (Opzelura) for atopic dermatitis. Med Lett Drugs Ther 2022; 64:12.
- Drugs for atopic dermatitis. Med Lett Drugs Ther 2020; 62:89.
- EW Seger et al. Relative efficacy of systemic treatments for atopic dermatitis. J Am Acad Dermatol 2019; 80:411. doi:10.1016/j.jaad.2018.09.053
- A Wollenberg et al. Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb. J Allergy Clin Immunol 2019; 143:135. doi:10.1016/j.jaci.2018.05.029
- M Nogueira and T Torres. Janus kinase inhibitors for the treatment of atopic dermatitis: focus on abrocitinib, baricitinib, and upadacitinib. Dermatol Pract Concept 2021; 11:e2021145. doi:10.5826/dpc.1104a145
- A Wollenberg et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol 2021; 184:437. doi:10.1111/bjd.19574
- JI Silverberg et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol 2021; 184:450. doi:10.1111/bjd.19573
- RA Panettieri Jr et al. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. Lancet Respir Med 2018; 6:511. doi:10.1016/s2213-2600(18)30184-x
- EL Simpson et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomized, placebo-controlled, phase 3 trial. Lancet 2020; 396:255. doi:10.1016/s0140-6736(20)30732-7
- JI Silverberg et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 2020; 156:863. doi:10.1001/jamadermatol.2020.1406
- T Bieber et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med 2021; 384:1101. doi:10.1056/nejmoa2019380
- E Guttman-Yassky et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet 2021; 397:2151. doi:10.1016/s0140-6736(21)00588-2
- K Reich et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 2021; 397:2169. doi:10.1016/s0140-6736(21)00589-4
- A Blauvelt et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 2021; 157:1047. doi:10.1001/jamadermatol.2021.3023
- A Blauvelt et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol 2022; 86:104. doi:10.1016/j.jaad.2021.05.075
- JI Silverberg et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: week 52 AD Up study results. J Allergy Clin Immunol 2021; 149:977. doi:10.1016/j.jaci.2021.07.036
- In brief: New warnings for Janus kinase inhibitors. Med Lett Drugs Ther 2021; 63:160.
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2023 January 25 (epub). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Three Drugs for Atopic Dermatitis (Adbry, Cibinqo, and Rinvoq)
Article code: 1673b
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
